تقرير
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
| العنوان: | Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis |
|---|---|
| المؤلفون: | Azienda Ospedaliera Ospedali Riuniti Marche Nord |
| المساهمون: | Armando Gabrielli, Full Professor Internal Medicine |
| المصدر: | Tn S, Hu W, N L, L H, Xu H, Xo SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavus (COV-19) Pneumon Two Patnts Wh Lung Cancer. J Thorac Oncol. 2020 May;15(5):700-704. do 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28. Ashour HM, Elkhat WF, Rahman MM, Elshabrawy HA. shts to the Recent 2019 Novel Coronavus (SARS-CoV-2) Lht of Past Human Coronavus Outbreaks. Pathogens. 2020 Mar 4;9(3):186. do 10.3390/pathogens9030186. Channappanavar R, Perlman S. Pathogen human coronavus fectns: causes and consequences of cytoke storm and munopathology. Sem munopathol. 2017 Jul;39(5):529-539. do 10.1007/s00281-017-0629-x. Epub 2017 May 2. Zumla A, polo G, NtoumF, Seyfert-Margols V, Nagu TJ, Clo D, Chakaya JM, Mara B, Maeurer M. Host-dected theraps and holt care for tuberculos. Lancet Resp Med. 2020 Apr;8(4):337-340. do 10.1016/S2213-2600(20)30078-3. Epub 2020 Feb 27. No abstract avaable. Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia |
| الوصول الحر: | https://clinicaltrials.gov/ct2/show/NCT04315480Test |
| قاعدة البيانات: | ClinicalTrials.gov |
| الوصف غير متاح. |